Morgan Stanley Maintains Overweight on Seagen, Raises Price Target to $180
Morgan Stanley analyst Matthew Harrison maintains Seagen (NASDAQ:SGEN) with a Overweight and raises the price target from $173 to $180.
Morgan Stanley Maintains Equal-Weight on Seagate Tech Hldgs, Lowers Price Target to $89
Morgan Stanley analyst Katy Huberty maintains Seagate Tech Hldgs (NASDAQ:STX) with a Equal-Weight and lowers the price target from $95 to $89.
Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Raises Price Target to $80
Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and raises the price target from $74 to $80.
Morgan Stanley Maintains Equal-Weight on Rhythm Pharmaceuticals, Raises Price Target to $8
Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $4 to $8.
Morgan Stanley Maintains Equal-Weight on Regency Centers, Lowers Price Target to $57.5
Morgan Stanley analyst Richard Hill maintains Regency Centers (NASDAQ:REG) with a Equal-Weight and lowers the price target from $63 to $57.5.
Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $19
Morgan Stanley analyst David Lewis maintains Pulmonx (NASDAQ:LUNG) with a Equal-Weight and lowers the price target from $30 to $19.
Morgan Stanley Maintains Equal-Weight on Physicians Realty Trust, Lowers Price Target to $16
Morgan Stanley analyst Richard Hill maintains Physicians Realty Trust (NYSE:DOC) with a Equal-Weight and lowers the price target from $17.5 to $16.
Morgan Stanley Maintains Equal-Weight on Phillips Edison, Lowers Price Target to $31
Morgan Stanley analyst Richard Hill maintains Phillips Edison (NASDAQ:PECO) with a Equal-Weight and lowers the price target from $32 to $31.
Morgan Stanley Maintains Equal-Weight on Phillips 66, Raises Price Target to $105
Morgan Stanley analyst Connor Lynagh maintains Phillips 66 (NYSE:PSX) with a Equal-Weight and raises the price target from $100 to $105.
Morgan Stanley Maintains Underweight on Pentair, Lowers Price Target to $41
Morgan Stanley analyst Joshua Pokrzywinski maintains Pentair (NYSE:PNR) with a Underweight and lowers the price target from $49 to $41.